Scarica l'app Stockscreener
25.09
0.04%
0.01
Dopo l'orario di chiusura:
25.56
0.47
+1.87%
Precedente Chiudi:
$25.08
Aprire:
$24.12
Volume 24 ore:
229.96K
Relative Volume:
2.84
Capitalizzazione di mercato:
$1.51B
Reddito:
-
Utile/perdita netta:
$-209.84M
Rapporto P/E:
-5.4902
EPS:
-4.57
Flusso di cassa netto:
$-6.73M
1 W Prestazione:
-2.11%
1M Prestazione:
+0.00%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$24.00
$27.01
Intervallo di 1 settimana:
$22.92
$27.01
Portata 52W:
$16.50
$27.68
Damora Therapeutics Inc Stock (DMRA) Company Profile
Nome
Damora Therapeutics Inc
Settore
Industria
Telefono
(781) 281-9020
Indirizzo
221 CRESCENT STREET, WALTHAM
Compare DMRA vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DMRA
Damora Therapeutics Inc
|
25.09 | 1.51B | 0 | -209.84M | -6.73M | -4.57 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Damora Therapeutics Inc Stock (DMRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-25 | Iniziato | Evercore ISI | Outperform |
| 2026-02-17 | Iniziato | UBS | Buy |
| 2026-01-07 | Iniziato | Leerink Partners | Outperform |
| 2025-12-01 | Iniziato | Guggenheim | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-11-23 | Iniziato | BofA Securities | Buy |
| 2020-11-23 | Iniziato | Credit Suisse | Outperform |
| 2020-11-23 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Damora Therapeutics Inc Borsa (DMRA) Ultime notizie
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Trends and Sentiment 2026 - MarketBeat
Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - marketbeat.com
Damora Therapeutics, Inc. Common Stock (DMRA) 10K Form and Latest SEC Filings 2026 - MarketBeat
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Stock Price Up 8.5%What's Next? - MarketBeat
Did Damora’s New Biopharma Heavyweight Leadership Just Reshape Damora Therapeutics' (DMRA) Investment Narrative? - Sahm
Damora Therapeutics, Inc. Common Stock (DMRA) Earnings Date and Reports 2026 - MarketBeat
Damora Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
DMRA Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - bitget.com
New Damora CEO gets 2 million-share hiring package under Nasdaq rule - Stock Titan
ETFs Investing in Damora Therapeutics, Inc. Stocks - TradingView
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Short Interest Update - marketbeat.com
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Given Average Rating of "Moderate Buy" by Analysts - marketbeat.com
DMRA (Damora Therapeutics) PB Ratio : (As of Mar. 28, 2026) - GuruFocus
DMRA PE Ratio & Valuation, Is DMRA Overvalued - Intellectia AI
DMRA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Trading Down 9.6%Time to Sell? - MarketBeat
Damora Therapeutics Inc (DMRA) Stock Earnings Transcripts - GuruFocus
Damora Therapeutics Inc (DMRA) Stock Price & 30 Year Financial Data - GuruFocus
This Vertiv Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Sahm
Damora Therapeutics (DMRA) grants 250,000 stock options to General Counsel - Stock Titan
Damora Therapeutics director granted 37,313 options | DMRA Insider Trading - Stock Titan
Damora Therapeutics (DMRA) director receives 37,313-share stock option grant - Stock Titan
Damora Therapeutics (DMRA) insiders receive 37,313-share option grant via Fairmount - Stock Titan
Damora Therapeutics (DMRA) director option grant tied to Fairmount funds - stocktitan.net
Damora Therapeutics (DMRA) director awarded 37,313 stock options - Stock Titan
Damora Therapeutics (DMRA) director files Form 3 initial ownership report - Stock Titan
Damora Therapeutics (NASDAQ: DMRA) director Michael Landsittel files Form 3 - Stock Titan
Damora Therapeutics Inc (DMRA) DCF Valuation - GuruFocus
Damora Therapeutics Inc (DMRA) Insider Trading Activity | Apple Insider Buys and Sells - GuruFocus
Evercore ISI Group Initiates Coverage on DMRA with 'Outperform' - GuruFocus
Evercore ISI initiates Damora Therapeutics stock with outperform By Investing.com - Investing.com India
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Earns Outperform Rating from Analysts at Evercore - marketbeat.com
Evercore ISI initiates Damora Therapeutics stock with outperform - Investing.com
Damora Therapeutics Inc Azioni (DMRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):